To identify the molecular mechanisms underlying the ability of HMC to improve dyslipidemia, we investigated the expression of AMPK, the lipogenesis-related transcription factors PPARα and SREBP-1c, and the lipogenesis-related enzyme FAS, in the liver. Here, FAS is linked to metabolic syndrome.